



April 20, 2024

✓ **BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

**National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**Mumbai - 400 051.**

***Dear Sir/Madam,***

**Sub: Disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('Listing Regulations').**

We are pleased to enclose a Press Release regarding launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the U.S. FDA.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the Listing Regulations.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**

**Encl: a/a.**

## Lupin Launches Mirabegron Extended-Release Tablets in the United States

**Mumbai, Naples, April 20, 2024:** Global pharma major Lupin Limited (Lupin) today announced the launch of Mirabegron Extended-Release Tablets, 25 mg, in the United States, after having received an approval from the United States Food and Drug Administration (U.S. FDA).

Mirabegron Extended-Release Tablets, 25 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 25 mg of Astellas Pharma Global Development, Inc.

Mirabegron Extended-Release Tablets, 25 mg had estimated annual sales of USD 1,019 million in the U.S. (IQVIA MAT February 2024).

### About Lupin

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.

The Company enjoys a leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas. Lupin is the third-largest pharmaceutical company in the U.S. by prescriptions. The company invested 7.9% of its revenue in research and development in FY23.

Lupin has 15 manufacturing sites, 7 research centers, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on:

Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

**For further information or queries please contact –  
Heena Dhedhi**

Deputy General Manager – Corporate Communications

Email: [heenadhedhi@lupin.com](mailto:heenadhedhi@lupin.com)

### \*Safe Harbor Statement

Myrbetriq® is a registered trademark of Astellas Pharma Inc.